Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 2,666,410 shares, a growth of 28.6% from the December 15th total of 2,073,310 shares. Based on an average daily volume of 2,698,186 shares, the days-to-cover ratio is currently 1.0 days. Currently, 7.5% of the company’s shares are sold short. Currently, 7.5% of the company’s shares are sold short. Based on an average daily volume of 2,698,186 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Oliver Luxxe Assets LLC acquired a new stake in Gain Therapeutics during the 4th quarter worth $65,000. JPMorgan Chase & Co. acquired a new position in Gain Therapeutics during the third quarter worth $47,000. Virtu Financial LLC boosted its position in shares of Gain Therapeutics by 126.9% in the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after buying an additional 30,207 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Gain Therapeutics in the third quarter valued at about $68,000. Finally, Benedict Financial Advisors Inc. grew its holdings in Gain Therapeutics by 55.6% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock valued at $62,000 after buying an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 11.97% of the company’s stock.

Wall Street Analyst Weigh In

GANX has been the topic of a number of analyst reports. Roth Capital reissued a “buy” rating and issued a $10.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and set a $9.00 target price on shares of Gain Therapeutics in a research note on Wednesday, October 15th. Finally, Maxim Group upped their price objective on Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Gain Therapeutics Stock Down 3.7%

Shares of Gain Therapeutics stock traded down $0.07 on Monday, reaching $1.81. The stock had a trading volume of 1,842,540 shares, compared to its average volume of 1,711,706. The stock has a market capitalization of $69.61 million, a P/E ratio of -2.97 and a beta of 0.06. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The company has a 50 day moving average price of $3.05 and a 200 day moving average price of $2.22.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). As a group, equities research analysts forecast that Gain Therapeutics will post -1 EPS for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.